New UK-China biotech collaboration to develop shingles vaccine
Vaccitech will combine Oxford University vaccine know-how with the manufacturing expertise of China’s CanSino Biologics in collaboration focused on herpes zoster. Oxford, UK and Tianjin, China – 14th September 2018 – FOR IMMEDIATE RELEASE
2018-09-14 READ MORE
National Research Council contribution plays key role in newly approved Ebola vaccine
March 20, 2018 – Montreal, QC - In response to the Ebola outbreak that claimed more than 10,000 lives in West Africa four years ago, Canada and China worked on a new Ebola vaccine.
2018-03-22 READ MORE
CanSino Submits a Clinical Trial Application for the Component DTP Diptheria Tetanus Pertussis Combo Vaccine (Adults, Teenagers and Children Above 6 Years Old)
August 2 nd 2016, Tianjin CanSino submits the Clinical trial applicationfor the component DTP combo vaccine andsuccessfullyreceives the “drug application registration”. This product is the first DTP vaccine ...
2016-08-03 READ MORE
World TB Day is March 24. Help us bring an end to the epidemic by supporting TB vaccine research.
Ridding the World of Tuberculosis
2016-03-24 READ MORE
Cansino Biotechnology: Meningococcal Group AC Bivalent Conjugate Vaccine, Freeze Dried is Approved for Clinical Trial
Meningococcal Group AC Bivalent Conjugate Vaccine, Freeze Dried (MCV2) developed by Tianjin Cansino Biotechnology has been approved for clinical trial by China Food ...
2016-02-15 READ MORE
Copyright © ( 2017) CanSino Biologics Inc
For the record: 津ICP备14006666号-2